"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Human vaccines & immunotherapeutics Ročník 18; číslo 3; s. 1889449
Hlavní autoři:	Sollena, Pietro, Cappilli, Simone, Federico, Francesco, Schinzari, Giovanni, Tortora, Giampaolo, Peris, Ketty
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Taylor & Francis 31.05.2022 Taylor & Francis Group
Témata:	Advanced melanoma Antibodies, Monoclonal - adverse effects Antineoplastic Agents, Immunological - adverse effects CTLA-4 Antigen - antagonists & inhibitors CTLA-4 inhibitors cutaneous adverse events Exanthema - chemically induced Humans immune checkpoint inhibitors Immunotherapy - adverse effects Melanoma - drug therapy Melanoma – Mini-Review PD-1 inhibitors skin rash skin rash cutaneous adverse events PD-1 inhibitors immune checkpoint inhibitors Advanced melanoma CTLA-4 inhibitors
ISSN:	2164-5515, 2164-554X, 2164-554X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!